Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Kidney disease manifests clinically as elevated albumin excretion rate (AER), impaired glomerular filtration rate (GFR), or both, and is a cause of substantial morbidity and mortality in type 1 diabetes (T1D). The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study tested whether intensive diabetes therapy (INT) aimed at lowering glucose concentrations as close as safely possible to the normal range reduces the risks of kidney disease and other diabetes complications. RESEARCH DESIGN AND METHODS: In the DCCT, 1,441 participants with T1D were randomly assigned to INT or conventional diabetes therapy (CON) for a mean duration of 6.5 years. Subsequently, participants have been followed for 18 years in the ongoing observational EDIC. Standardized longitudinal measurements of AER, estimated GFR, and blood pressure were made throughout the DCCT/EDIC. RESULTS: During the DCCT, INT reduced the risks of incident microalbuminuria (AER ≥40 mg/24 h) and macroalbuminuria (AER ≥300 mg/24 h) by 39% (95% CI 21–52%) and 54% (29–74%), respectively. During EDIC years 1–8, participants previously assigned to DCCT INT continued to experience lower rates of incident microalbuminuria and macroalbuminuria, with risk reductions of 59% (39–73%) and 84% (67–92%), respectively. Beneficial effects of INT on the development of impaired GFR (sustained estimated GFR <60 mL/min/1.73 m2) and hypertension became evident during combined DCCT/EDIC follow-up, with risk reductions of 50% (18–69%) and 20% (6–21%), respectively, compared with CON. CONCLUSIONS: In the DCCT/EDIC, INT resulted in clinically important, durable reductions in the risks of microalbuminuria, macroalbuminuria, impaired GFR, and hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this section, the focus is on CKD attributed to diabetes in adults, which occurs in 20-40% of people with diabetes (1-4).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In RCTs, targeting lower HbA1c values using glucose-lowering medications has been proven to reduce risks of microvascular diabetes complications (i.e., kidney disease, retinopathy, neuropathy) and, in some studies, also macrovascular diabetes complications (i.e., cardiovascular events).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both T1D or T2D, lower achieved levels of HbA1c < 7% ( < 53 mmol/mol) versus 8% -9% (64 -75 mmol/mol) reduce risk of overall microvascular complications, including nephropathy and retinopathy, and macrovascular complications in some RCTs. 189 -193”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“while the glucose-lowering effects of SGLT2 inhibitors are blunted with eGFR <45 mL/min/1.73m 2 , the kidney and cardiovascular benefits were still seen at eGFR levels as low as 20 mL/min/ 1.73 m 2 even with no significant change in glucose (4,29,31,107,123,127,129,130).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Hyperglycemia is a known risk factor for the development and progression of both DPN and CKD.9–12”
From Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease (2020) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · cited 1×
“A large body of evidence demonstrates that hyperglycemia contributes to the damage of target organs, including the kidney (5).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102 · cited 1×
“The Chronic Kidney Disease Epidemiology Collaboration equation was used to estimate GFR from calibrated serum creatinine, age, sex, and race (13).”
MethodNathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832 · cited 2×
“The DCCT enrolled 1,441 people with T1D from 1983–1989 to determine the effects of INT on the long-term complications of diabetes (7,9).”
BackgroundMethod(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
Andersen, A. R., Christiansen, J. S., Andersen, J. K., Kreiner, S., & Deckert, T. (1983) · Diabetologia · doi:10.1007/bf00284458 · Cited by 1,067 · cited 1×
“In early cohort studies, up to 40% of patients with T1D developed macroalbuminuria (AER $300 mg/24 h), and up to 75% of these patients progressed to end-stage renal disease (ESRD) within 10 years (1,2).”
BackgroundIntensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
Cited by
Items 101–200 of 252
Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad144 · Cited by 25
Ding, L., Hou, Y., Liu, J., Wang, X., Wang, Z., Ding, W., & Zhao, K. (2023) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2023.09.005 · Cited by 24
Huang, Q., Yang, D., Deng, H., Liang, H., Zheng, X., Yan, J., Xu, W., Liu, X., Yao, B., Luo, S., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0240 · Cited by 23
“The DCCT study has shown that intensive glycemic control significantly reduced the risk of microvascular complications in patients with T1DM [40,41].”
Shah, H., McGill, J. B., Hirsch, I. B., Wu, C.-Y., Gałecki, A. T., de Boer, I. H., Mauer, M. S., & Doria, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae044 · Cited by 24
Taboko, N. E., Assob, J. C. N., Feteh, V. F., & Choukem, S. P. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2804-5 · Cited by 28
“Prospective diabetes trials have proved the importance of optimal glycemic control in preventing the occurrence and progression of diabetic complications including microalbuminuria [26].”
BackgroundHuang, C., Ting, W., Lo, F., Tsai, J.-D., Sun, F., Chan, C.-I., Chiang, Y.-T., Lin, C., Cheng, B.-W., Wu, Y., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2017.09.015 · Cited by 23
Braffett, B. H., Bebu, I., Lorenzi, G. M., Martin, C. L., Perkins, B. A., Gubitosi‐Klug, R., & Nathan, D. M. (2025) · Diabetes Care · doi:10.2337/dc24-2885 · Cited by 28
Cummings, L. A. M., Clarke, A. B. M., Sochett, E. B., Daneman, D., Cherney, D. Z. I., Reich, H. N., Scholey, J. W., Dunger, D. B., & Mahmud, F. H. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.03.030 · Cited by 21
“Although poor glycemic control is a recognized risk factor for diabetic renal disease, differences in glycemic control and/or transient hyperglycemia do not fully account for the observed relationship between eGFR, filtration status, and social marginalization in this study.(39) Minority youth are disproportionately a…”
BackgroundDiabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 22
“ДН развивается у 20–40% пациентов с СД 1 [18], типично развитие при длительности заболевания более 10 лет, однако при неблагоприятных факторах возможно более раннее развитие.”
Advances in the management of diabetes: new devices for type 1 diabetes
Wunna, W., Tsoutsouki, J., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138016 · Cited by 25
HbA1c Variability as an Independent Risk Factor for Microvascular Complications in Type 1 Diabetes
Mao, Y., & Zhong, W. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221100833 · Cited by 20
Targeting DNA methylation in diabetic kidney disease: A new perspective
Akhouri, V., Majumder, S., & Gaikwad, A. B. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122256 · Cited by 21
Neighborhood context and kidney disease in Philadelphia
Boyle, S. M., Zhao, Y., Chou, E. Y., Moore, K., & Harhay, M. N. (2020) · SSM - Population Health · doi:10.1016/j.ssmph.2020.100646 · Cited by 19
Elnaem, M. H., Mansour, N. O., Nahas, A. R. F., Baraka, M. A., Elkalmi, R. M., & Cheema, E. U. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s285191 · Cited by 20
“Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a major microvascular complication that occurs in 20–40% of diabetic patients.(2) Screening for diabetic nephropathy is typically recommended 5 years after diagnosis in type 1 diabetes and should be considered at the time of diagnosis in type 2 diab…”
BackgroundAttenuated kidney oxidative metabolism in young adults with type 1 diabetes
Choi, Y. J., Richard, G. M., Zhang, G., Hodgin, J. B., Demeke, D., Yang, Y., Schaub, J. A., Tamayo, I. M., Gurung, B. K., Naik, A. S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183984 · Cited by 24
Limonte, C. P., Gao, X., Bebu, I., Seegmiller, J. C., Karger, A. B., Lorenzi, G. M., Molitch, M. E., Karanchi, H., Perkins, B. A., de Boer, I. H., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2196 · Cited by 18
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes
de Boer, I. H., & Bakris, G. L. (2018) · Diabetes Care · doi:10.2337/dci17-0053 · Cited by 18
The influence of food order on postprandial glucose levels in children with type 1 diabetes
Faber, E. M., van Kampen, P. M., Boers, A. C.-D., Houdijk, E. C. A. M., & van der Kaay, D. C. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12640 · Cited by 20
Regression and progression of microalbuminuria in adolescents with childhood onset diabetes mellitus
Son, M. K., Yoo, H. Y., Kwak, B. O., Park, H. W., Kim, K. S., Chung, S., Chae, H. W., Kim, H.-S., & Kim, D. H. (2015) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2015.20.1.13 · Cited by 19
The impact of diabetes on heart failure development: The cardio-renal-metabolic connection
Valensi, P. E., Prévost, G., Pinto, S., Halimi, J., & Donal, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108831 · Cited by 20
Zhang, F., Han, Y., Zheng, G., & Li, W. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s451628 · Cited by 21
Diabetes Complications in Childhood Diabetes: New Biomarkers and Technologies
Bjornstad, P., & Maahs, D. M. (2015) · Current Pediatrics Reports · doi:10.1007/s40124-015-0081-0 · Cited by 16
Xiong, Y., Zhu, W., Xu, Q., Ruze, R., Yan, Z., Li, J., Hu, S., Zhong, M., Cheng, Y., & Zhang, G. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04611-3 · Cited by 17
“mission of albuminuria and amelioration of diabetic renal injury [53].”
BackgroundThe epigenetic regulation of podocyte function in diabetes
Majumder, S., & Advani, A. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.015 · Cited by 18
Norman, G. J., Fernandes, J., Nemlekar, P. M., Andrade, S. B., Lupton, L. L., & Berk, A. R. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.24255 · Cited by 21
Schnell, O., Valensi, P. E., Standl, E., & Ceriello, A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.129 · Cited by 15
Educational outcomes among children with type 1 diabetes: Whole‐of‐population linked‐data study
Begum, M., Chittleborough, C., Pilkington, R. M., Mittinty, M., Lynch, J. W., Penno, M. A. S., & Smithers, L. G. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13107 · Cited by 20
Limonte, C. P., Valo, E., Montemayor, D., Afshinnia, F., Ahluwalia, T. S., Costacou, T., Darshi, M., Forsblom, C. M., Hoofnagle, A. N., Groop, P., et al. (2020) · American Journal of Nephrology · doi:10.1159/000510830 · Cited by 15
Hueros, J. I. C., Hidalgo-Barquero, M. V. M., Morales-Gabardino, J. A., & Buitrago, F. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.11.015 · Cited by 16
T Cells Mediate Kidney Tubular Injury via Impaired PDHA1 and Autophagy in Type 1 Diabetes
Wang, C., Lu, W., Chiang, S., Tsai, T., Liu, S., Hsieh, C., Su, P., Huang, C., Tsai, F., Lin, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac378 · Cited by 15
Nguyen, H. T., Tuan, A. N., Thi, T. A. D., Van, K. T., Le-Nhat-Thuy, G., Thị, P. H., Thi, Q. G. N., Cham, B. T., Quang, H. T., & Nguyen, T. V. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129566 · Cited by 14
Biomarkers of tubulointerstitial damage and function in type 1 diabetes
de Boer, I. H., Gao, X., Bebu, I., Hoofnagle, A. N., Lachin, J. M., Paterson, A. D., Perkins, B. A., Saenger, A. K., Steffes, M. W., Zinman, B., et al. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000461 · Cited by 14
Takao, T., Matsuyama, Y., Suka, M., Yanagisawa, H., & Kasuga, M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.005 · Cited by 15
Felício, J. S., Araújo, M. A. M., de Lemos, G. N., Fernandes, I. J., Ruivo, L. O., Chambouleyron, E., Silva, L. D. S. D., Nunes, C. F., Paes, G. M. D. A., de Melo, F. T. C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02666-z · Cited by 16
Zhang, Y., Xia, Y., Chang, Q., Ji, C., Zhao, Y., & Zhang, H. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad042 · Cited by 14
Tuttle, K. R., Reynolds, C. L., Kornowske, L. M., Jones, C. R., Alicic, R. Z., Daratha, K. B., Neumiller, J. J., Greenbaum, C. J., Pavkov, M. E., Xu, F. Z., et al. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101130 · Cited by 13
Inzucchi, S. E., & Majumdar, S. K. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.018 · Cited by 15
McEwan, P. C., Bennett, H., Fellows, J., Priaulx, J., & Bergenheim, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162441 · Cited by 15
Glycemic status and chronic kidney disease in C hinese adults: F indings from the REACTION study
Lin, L., Lu, J., Chen, L., Mu, Y., Ye, Z., Liu, C., Chen, G., Shi, L., Zhao, J., Li, Q., et al. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12490 · Cited by 14
Limonte, C. P., Lamprea-Montealegre, J. A., & Tuttle, K. R. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151520 · Cited by 14
Kidney Disease: The Forgotten Legacy of Type 1 Diabetes
Thomas, M. C., Zoungas, S., Hanssen, N. M. J., McAuley, S. A., & Cooper, M. E. (2025) · Diabetes Care · doi:10.2337/dci25-0028 · Cited by 20
Zhao, P., Li, N., Lin, L., Li, Q., Wang, Y., & Luo, Y. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2134026 · Cited by 10
Effects of Root Extract of Ruellia tuberosa L. on Kidneys of Diabetic Rats
Safitri, A., Srihardyastutie, A., Roosdiana, A., Aulanni’am, A., & Octaviana, E. N. L. (2019) · Journal of Mathematical and Fundamental Sciences · doi:10.5614/j.math.fund.sci.2019.51.2.3 · Cited by 14
Juckett, L., Hariharan, G., Dodonova, D. C., Klaus, J., Rowe, M. L., Burak, E., Mason, B., & Bunck, L. E. (2022) · Nutrients · doi:10.3390/nu14050944 · Cited by 11
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
Quantitative levels of serumN-glycans in type 1 diabetes and their association with kidney disease
Colombo, M., Shehni, A. A., Thoma, I., McGurnaghan, S. J., Blackbourn, L. A. K., Wilkinson, H., Collier, A., Patrick, A. W., Petrie, J. R., McKeigue, P., et al. (2020) · Glycobiology · doi:10.1093/glycob/cwaa106 · Cited by 13
Fernández-Fernández, L., Barquilla-García, A., Sánchez-Vega, J., Risco-Solanilla, J. C., González, F. S., & Buitrago, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132886 · Cited by 9
Fliser, D., Dellanna, F., Koch, M., and, Wiggenhauser, A., & on behalf of the PRIMAVERA study group (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw418 · Cited by 9
Alterations of Renal Function in Patients with Diabetic Kidney Disease: A BOLD and DTI Study
Wei, X., Hu, R., Zhou, X., Ni, L., Zha, D., Feng, H. A., Xu, H., & Wu, X. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/6844102 · Cited by 8
“DKD has been reported to have an incidence of 20%∼ 40% in diabetic patients in European and American countries [2, 3].”
BackgroundPotential Medicinal Value of Rhein for Diabetic Kidney Disease
Mao, X., Xu, D., Yue, S., Fu, R., Zhang, S., & Tang, Y. (2023) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-3591-y · Cited by 10
“Until now, surgical treatment has mostly referred to metabolic surgery and kidney transplantation, which is mainly used for the renal failure stage of DKD.((34,35)) Medication is mainly used to control risk factors, such as hyperglycemia, hypertension and hyperlipidemia.”
MethodCellular and molecular aspects of diabetic nephropathy; the role of VEGF-A
Carranza, K., Verón, D., Cercado, A. G., Bautista, N., Pozo, W., Tufró, A., & Verón, D. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.05.003 · Cited by 8
Yang, C.-C., Lin, C.-H., Wang, N., Lai, C., Lo, F., & The Chang Gung Juvenile Diabetes Eye Study Group (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00429 · Cited by 8
“The DCCT and Epidemiology of Diabetes Interventions and Complications (EDIC) study (31) demonstrated the benefits of intensive treatment for T1DM.”
Backgroundde Boer, I. H., Zelnick, L. R., Lin, J., Schaumberg, D. A., Wang, L., RUZINSKI, J. T., Friedenberg, G., Duszlak, J., Bubes, V. Y., Hoofnagle, A. N., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.09.014 · Cited by 11
Li, S., Li, L., Chen, X., Liu, S., Gao, M., Cheng, X., & Li, C. (2024) · BMC Public Health · doi:10.1186/s12889-024-20317-y · Cited by 8
Wang, X., Zheng, K., Hu, X., & Pei, J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112163 · Cited by 12
Perkins, B. A., Bebu, I., Gao, X., Karger, A. B., Hirsch, I. B., Karanchi, H., Molitch, M. E., Zinman, B., Lachin, J. M., & de Boer, I. H. (2022) · Diabetes Care · doi:10.2337/dc21-1883 · Cited by 9
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
Perkins, B. A., Bebu, I., de Boer, I. H., Molitch, M. E., Zinman, B., Bantle, J. P., Lorenzi, G. M., Nathan, D. M., & Lachin, J. M. (2022) · Diabetes Care · doi:10.2337/dc22-1420 · Cited by 8
Мураталина, А., Smith‐Palmer, J., Nurbekova, A., Abduakhassova, G., Zhubandykova, L., Roze, S., Karamalis, M., Shamshatova, G., Demessinov, A., D’Agostino, N. D., et al. (2015) · Value in Health Regional Issues · doi:10.1016/j.vhri.2015.09.002 · Cited by 8
Diabetes and Long-Term Complications
Cagliero, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00051-2 · Cited by 11
Pahuja, V., Punjot, P., Fernandes, G., & Chatterjee, N. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00735-0 · Cited by 7
“Suboptimal glycemic control subsequently increases the risk of adverse outcomes such as cardiovascular disease [10], amputation [11], retinal diseases [12], and kidney disease [13].”
BackgroundToyama, T. (2020) · Springer eBooks · doi:10.1007/978-981-15-9301-7_1 · Cited by 7
Khatri, M., Ryan, C. M., Gao, X., de Boer, I. H., Braffett, B. H., Molitch, M. E., Karger, A. B., Lorenzi, G. M., Lee, P., Trapani, V. R., et al. (2023) · Kidney360 · doi:10.34067/kid.0000000000000178 · Cited by 7
Marchetti, J., Balbino, K. P., Hermsdorff, H. H. M., Juvanhol, L. L., Martínez, J. A., & Steemburgo, T. (2021) · Lifestyle Genomics · doi:10.1159/000516118 · Cited by 8
Vakali, E., Rigopoulos, D., Carrillo, A. E., Flouris, A. D., & Dinas, P. C. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210914103329 · Cited by 9
Rates of diabetic retinopathy among cluster analysis—identified type 2 diabetic mellitus subgroups
Scott, R. A., Lu, V. I., Grove, N. C., Patnaik, J. L., & Manoharan, N. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06260-5 · Cited by 6
Grace, T., Edgington, A., Reinhart, L., Burkart, T., Dyer, E., Halsey, J., Baroudi, K., Hicks, C., Layne, J. E., & Walker, T. C. (2024) · Clinical Diabetes · doi:10.2337/cd24-0030 · Cited by 7
Carbohydrate counting as a strategy to optimize glycemic control in type 1 diabetes mellitus
Centenaro, A., do Nascimento, C., Beretta, M. V., & Rodrigues, T. D. C. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000596 · Cited by 12
Pathophysiology of Diabetic Nephropathy
Herman‐Edelstein, M., & Doi, S. Q. (2016) · Springer eBooks · doi:10.1007/978-3-319-43359-2_4 · Cited by 7
Curovic, V. R., Roy, N., Hansen, T. W., Caramori, M. L., Cherney, D. Z. I., de Boer, I. H., Emanuele, M. A., Hirsch, I. B., Lingvay, I., McGill, J. B., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110119 · Cited by 4
Zhang, J., Guo, Y., Wei, C., Yu, Y., Shan, H., Wu, B., & Wu, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1363501 · Cited by 5
Chen, Y.-X., Hu, D.-S., Lin, M.-X., Gao, Z.-H., Hong, H.-Z., Hu, Y., Yao, L., Cui, G.-W., & Wang, L. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2472981 · Cited by 7
“diabetic kidney disease (dKd) is a prevalent chronic consequence of type 2 diabetes mellitus (t2dM), affecting around 20% to 40% of t2dM patients [1,2].”
Miele, F., Clementi, S., Gennaro, R., Nicolao, I., Romanelli, T., Speese, K., & Piras, E. M. (2019) · JMIR Diabetes · doi:10.2196/11343 · Cited by 6
“In the medium-to-long term, patients with poorly controlled diabetes may develop serious health issues, such as cardiovascular diseases [46,47], retinopathies [48,49], or renal diseases [50,51].”
Glycemic Control Assessment in the Dialysis Patient: Is Glycated Albumin the Answer?
Molitch, M. E. (2017) · American Journal of Nephrology · doi:10.1159/000485844 · Cited by 4
Wasser, W. G., Gil, A., & Skorecki, K. L. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10214 · Cited by 5
Longitudinal Trajectories of Biomarkers of Kidney Tubular Function in Type 1 Diabetes
Limonte, C. P., Gao, X., Bebu, I., Seegmiller, J. C., Lorenzi, G. M., Perkins, B. A., Karger, A. B., Arends, V. L., Paterson, A. D., Molitch, M. E., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2023.11.030 · Cited by 3
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
A Multi-Marker Approach for Improved Glycemic Management in Diabetes Mellitus
Belle, J. T. L. (2017) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2017.04.00124 · Cited by 4
Sudoscan's Effectiveness in Identifying Chronic Kidney Disease in Patients With Type 2 Diabetes
Nica, A. E., Rusu, E., Dobjanschi, C. G., Rusu, F., Parlițeanu, O. A., Vinereanu, I.-V., Sivu, C., & Radulian, G. (2024) · Cureus · doi:10.7759/cureus.60344 · Cited by 4
“CKD occurs in 20% to 40% of adults with diabetes mellitus [2-5].”
BackgroundPrevalence and risk factors of diabetic kidney disease in north eastern Nigeria
Chiroma, I. K., Sulaiman, M. M., Mubi, B., Ndahi, A. A., Mamza, A. A., Lawan, M., Loskurima, U., Shettima, J., Amali, A. O., & Ummate, I. (2021) · Annals of African Medical Research · doi:10.4081/aamr.2020.135 · Cited by 3
Lee, D., Won, G. W., Lee, Y. H., Ku, E. J., Oh, T. K., & Jeon, H. J. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e171 · Cited by 3
Isidto, R., Danguilan, R. A., Naidas, O. D., Villanueva, R. T., Arakama, M.-H., & Paraiso, L. M. (2023) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s387262 · Cited by 5
Gonçalves, B. M., & Coelho, D. (2019) · Revista Española de Anestesiología y Reanimación (English Edition) · doi:10.1016/j.redare.2019.02.009 · Cited by 3
Gu, X., Meng, H., Liu, J., Liang, Y., Li, B., Wang, F., Liu, Q. S., Zhang, Z., Liang, J., Zhang, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.07.663452 · Cited by 4
Alsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.161004 · Cited by 6
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease
Karalliedde, J. J., Winocour, P. H., Chowdhury, T. A., De, P., Frankel, A., Montero, R., Pokrajac, A., Banerjee, D., Dasgupta, I., Fogarty, D. G., et al. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2021.328 · Cited by 2
Hacıoğlu, Y., Pişkinpaşa, M. E., Kılıçkaya, P., Niyazoğlu, M., Hacıoğlu, B., & Hatipoğlu, E. (2022) · Istanbul Medical Journal · doi:10.4274/imj.galenos.2022.44788 · Cited by 3
Saul Genuth, MD: Clinical Researcher and Leader in Developing Modern Diabetes Treatment
Jacobson, A. M., & Nathan, D. M. (2015) · Diabetes Care · doi:10.2337/dc14-1396 · Cited by 2
Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-1601 · Cited by 2
The Association Between Insulin Resistance And Advanced Renal Disease In Type 1 Diabetes
Duţă, I., Rusu, E., Costache, A., Radulian, G., & Ion, D. A. (2015) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2015-0021 · Cited by 2
“Fasting blood samples were assessed for lipids, HbA1c (glycated hemoglobin) and serum creatinine.”
BackgroundInfluentialA Methodology to Compare Insulin Dosing Recommendations in Real-Life Settings
Groat, D., Grando, A., Thompson, B., Neto, P. C. M., Soni, H., Boyle, M. E., Bailey, M., & Cook, C. B. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817704444 · Cited by 2
Diabetic Nephropathy in Children and Adolescents
Bjornstad, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_4 · Cited by 2
Moshenets, K. I. (2018) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2018-0047 · Cited by 2
Gonçalves, B. M., & Coelho, D. (2019) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2019.02.009 · Cited by 2
Prospective Study on Evidence Based Management of chronic Kidney Disease with Comorbidities
Habeeba, S., Fatima, R., Sabah, N. U., Sehar, N., Yousuf, S., Yezdani, U., & Khan, M. G. (2020) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v8i2.667 · Cited by 2
Jerums, G., Ekinci, E. I., Premaratne, E., Baker, S. T., Panagiotopoulos, S., & MacIsaac, R. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch62 · Cited by 3
Stratigou, T., Vallianou, N. G., Koutroumpi, S., Vlassopoulou, B., Apostolou, T., Tsagarakis, S., & Ioannidis, G. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0848-8076 · Cited by 1
Qarni, A. A. A., AlSubaiee, M., Husain, M., Alkhazmari, G., AlQahtani, A., Aldossary, I., Gado, W., Albahrani, Z., AlMukhaylid, S., Alarfaj, A., et al. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i2004 · Cited by 2
Sabbe, A. C. F., Bochanen, N., den Broucke, A. V., Mihaljčić, K., Bigaré, A., Dessel, K. V., Bouziotis, J., Ledeganck, K. J., Dirinck, E. L., Bolsens, N., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag380
Excess mortality in well-controlled T1DM without renal disease
Karalliedde, J. J., & Viberti, G. C. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.249 · Cited by 2
Do You Have Any Long-Term Health Conditions?
Rayner, H. C., Thomas, M., & Milford, D. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-23458-8_5 · Cited by 1
Metadata
- Authors
- de Boer, I. H., & for the DCCT/EDIC Research Group
- Affiliations
- Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, WA
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 24-30
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3867994
- OpenAlex
- W2160388935
- Semantic Scholar
- 0e25853fef3a739d11a78c1cdc288086bfda2756
- Cited by
- 254
- References
- 38
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 20 · 2023: 26 · 2022: 28 · 2021: 20 · 2020: 27 · 2019: 21 · 2018: 16 · 2017: 12 · 2016: 16 · 2015: 27 · 2014: 11 · 2013: 3
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, U01DK094176, U01-DK094157, RC4DK090766, R01DK088762, P30DK017047)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, diabetic nephropathy, urinary albumin excretion rate, microalbuminuria, macroalbuminuria, glomerular filtration rate, intensive diabetes therapy, glycemic control, hypertension, DCCT/EDIC
- MeSH terms
- Adolescent, Adult, Aged, Albuminuria, Blood Glucose, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypertension, Insulin, Kidney, Male, Middle Aged, Risk Factors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.